ALYI yields 51282.05% · ABBV yields 3.06%● Live data
📍 ALYI pulled ahead of the other in Year 1
Combined, ALYI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ALYI + ABBV for your $10,000?
Alternet Systems, Inc., through its subsidiaries, focuses on providing digital payments and data analytics, micro segmentation, and marketing intelligence services for the mass consumer goods, payments, financial services, and telecommunications sectors. It offers financial services software, including biometric authentication, multichannel payment solutions, electronic point of sale modernization, payment processing, and data analytics tools, as well as NFC point of sale solutions for the mobile financial industry. The company is also involved in the modernization of the electronics point of sale legacy infrastructure expanding the useful life of the electronic point of sale; and including new payment functions in the terminals, such as bill payment, electronic top-up, and native payments with digital currency at the point of sale. In addition, it provides data analytics tools and services for the telecommunications and financial services industries. Further, the company produces and sells electric motorcycles. The company holds a partnership with iQSTEL, Inc. to codevelop two-way device communication solutions specific to the EV operating environment. Alternet Systems, Inc. is headquartered in Miami, Florida.
Full ALYI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.